Bilcare Research
Home  |  Media  |  Contact Us
 
Increase text size Restore default text size Decrease text size
Media
Bilcare in News Media Kit Events Image GalleryDownload Center Media Contact
 
 

Press Releases


Pune, January 4, 2008

Bilcare Acquires Singular ID

Click here to download PDF


Bilcare Singapore Pte Ltd has bought 100% of Singular ID, the provider of integrated high technology enterprise brand security system, for a consideration of Singapore $ 19.58 million. Bilcare Singapore Pte Ltd is a wholly owned subsidiary of Bilcare Limited.

Creating and developing innovative and viable anti-counterfeit technologies & products has been one of the core Research initiatives at Bilcare. This acquisition underlines the importance that Bilcare places on offering state-of-the-art anti-counterfeit solutions, more particularly in the form of end user oriented and fully integrated systems.

"With counterfeit products not only affecting trust and safety of the consumer, but damaging the reputation and bottom line of the industry as well, there has been a dire need for a robust and scalable anti-counterfeit solution. I am delighted to bring Singular ID into the Bilcare group and greatly strengthen our vital product offerings", explained Mr. Mohan Bhandari, Chairman and Managing Director, Bilcare Limited.

About Singular ID Pte Ltd

Head-quartered in Singapore, and with a subsidiary in Padua, Northern Italy, Singular ID is a technology company engaged in research, development and creation of micro and nanotechnology based novel products. With a mission to safeguard customers' interests by providing integrated tagging solutions, Singular ID is a leading solution provider for tracing and authenticating items of value. Singular ID has a customer-centric approach and works closely with its clients to tailor its technology to meet specific customer requirements.

About Bilcare

Headquartered in India, Bilcare provides integrated packaging solutions across the pharmaceutical value chain through its key business activities; Pharma Packaging Research, Global Clinical Services and Research Academy. Bilcare operates state-of-the-art Manufacturing and Research facilities in India, Singapore, US & UK and has regional offices in Brazil, Germany, China & Australia which caters to global clients including J&J, Merck, GSK, Sanofi-Aventis, Pfizer, Novartis, Wyeth, Ranbaxy, and Dr. Reddy's. Bilcare partners with the global pharmaceutical sector by providing value solutions to address their key concerns viz. counterfeit, compliance, cost communication and convenience.

Media Contacts:

Corporate Voice | Weber Shandwick
Tele: 022- 40311219

For more information please contact:-
Bilcare Research
Tel: +91 20 30257700
Email: corpcomm@bilcare.com

 
 
 
 
 
 
 
© , Bilcare Limited. All Rights Reserved. Disclaimer Site Map Privacy Policy Content + Design Riteverses